CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients

Oncology Reports

Volumn 13, Issue 3, 2005, Pages 485-489

  Ohnishi, Takenao ^a   Ogawa, Yasuhiro ^a   Saibara, Toshiji ^a   Nishioka, Akihito ^a   Kariya, Shinji ^a   Fukumoto, Mitsutaka ^a   Onishi, Saburo ^a   Yoshida, Shoji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; CYP17 polymorphism; Estrogen; Hepatic steatosis; Non alcoholic steatohepatitis; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; STEROID 17ALPHA MONOOXYGENASE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FATTY LIVER; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGENS; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE; TAMOXIFEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 15044341781     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.3.485     Document Type: Article

References (21)

1. Wikken NR: Tamoxifen hits the target in situ. Lancet 353: 1986-1987, 1999.
2. Ogawa Y, Murata Y, Nishioka A, Inomata T and Yoshida S: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 351: 725, 1998. (Pubitemid 28105346)
3. Saibara T, Onishi S, Ogawa Y, Yoshida S and Enzan H: Nonalcoholic steatohepatitis. Lancet 354: 1299-1300, 1999.
4. Farrell GC: Drugs and steatohepatitis. Semin Liver Dis 22: 185-194, 2002.
5. Angulo P: Non-alcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
6. Kumar KS and Malet PF: Non-alcoholic steatohepatitis. Mayo Clin Proc 75: 733-739, 2000.
7. Mamounas EP: Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer. Clin Breast Cancer 2 (Suppl. 1): S20-S30, 2001.
8. Falck-Ytter Y, Younossi ZM, Marchesini G and McCullough AJ: Clinical features and natural history of non-alcoholic steatosis syndromes. Semin Liver Dis 21: 17-26, 2001. (Pubitemid 32240483)
9. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S and Yoshida S: Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7: 1299-1304, 2000.
10. Nishino M, Hayakawa K, Nakamura Y, Morimoto T and Mukaihara S: Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 180: 129-134, 2003. (Pubitemid 36008699)
11. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G and Fargion S: Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology 122: 274-280, 2002. (Pubitemid 34116980)
12. Shima Y, Tsukada T, Nakanishi K and Ohta H: Association of the Trp64Arg mutation of the beta3-adrenergic receptor with fatty liver and mild glucose intolerance in Japanese subjects. Clin Chim Acta 274: 167-176, 1998. (Pubitemid 28269299)
13. Iwamoto N, Ogawa Y, Kajihara S, Hisatomi A, Yasutake T, Yoshimura T, Mizuta T, Hara T, Ozaki I and Yamamoto K: Gln27Glu beta2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Clin Chim Acta 314: 85-91, 2001. (Pubitemid 33079186)
14. Nemoto Y, Toda K, Ono M, Fujikawa-Adachi K, Saibara T, Onishi S, Enzan H, Okada T and Shizuta Y: Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 105: 1819-1825, 2000. (Pubitemid 30421763)
15. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Misso ML, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S and Simpson ER: Aromatase-deficient (ArKO) mice accumulate excess adipose tissue. J Steroid Biochem Mol Biol 79: 3-9, 2001. (Pubitemid 34158772)
16. Picado-Leonard J and Miller WL: Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 6: 439-448, 1987. (Pubitemid 18085844)
17. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S and Williamson R: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3: 1873-1876, 1994. (Pubitemid 24310487)
18. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O and Kato T: Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60: 5710-5713, 2000.
19. Feigelson BE, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ and Henderson BE: Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58: 585-587, 1998. (Pubitemid 28099459)
20. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT and Hunter DJ: The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59: 1015-1020, 1999. (Pubitemid 29135960)
21. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ and de Vivo I: A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 61: 3955-3960, 2001. (Pubitemid 32720957)